Zacks Research Has Optimistic Outlook of FOLD Q1 Earnings

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Zacks Research increased their Q1 2027 earnings per share estimates for Amicus Therapeutics in a report released on Wednesday, July 9th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of $0.08 per share for the quarter, up from their prior forecast of $0.07. The consensus estimate for Amicus Therapeutics' current full-year earnings is $0.15 per share. Zacks Research also issued estimates for Amicus Therapeutics' FY2027 earnings at $0.47 EPS.

A number of other research analysts have also commented on the company. Wall Street Zen lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Monday, May 5th. UBS Group upped their price target on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Finally, The Goldman Sachs Group cut their target price on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $16.22.

Amicus Therapeutics Stock Performance

Shares of FOLD stock traded down $0.21 during trading hours on Thursday, reaching $6.09. 2,557,717 shares of the company's stock were exchanged, compared to its average volume of 3,232,018. Amicus Therapeutics has a fifty-two week low of $5.51 and a fifty-two week high of $12.65. The stock has a market capitalization of $1.88 billion, a P/E ratio of -67.66 and a beta of 0.51. The business has a fifty day moving average price of $6.07 and a 200-day moving average price of $7.76. The company has a quick ratio of 2.47, a current ratio of 3.34 and a debt-to-equity ratio of 2.02.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Virtus Fund Advisers LLC bought a new stake in Amicus Therapeutics in the fourth quarter valued at $29,000. Strs Ohio bought a new stake in Amicus Therapeutics in the first quarter valued at $30,000. Covestor Ltd grew its position in Amicus Therapeutics by 114.9% in the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after acquiring an additional 2,312 shares during the period. PNC Financial Services Group Inc. grew its position in Amicus Therapeutics by 211.4% in the first quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 3,497 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in Amicus Therapeutics in the first quarter valued at $53,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.